Ohtuvayre ensifentrine
Drug Class
Inhaled dual phosphodiesterase 3 and 4 (PDE3/PDE4) inhibitor吸入型磷酸二酯酶3和4（PDE3/PDE4）双重抑制剂
Mechanism
Ensifentrine acts as a dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), exerting both bronchodilator and anti-inflammatory effects in the airways.恩司芬群作为磷酸二酯酶3和4（PDE3和PDE4）的双重抑制剂，在气道中同时发挥支气管扩张和抗炎作用。
Approved Indication
Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.用于成人慢性阻塞性肺疾病（COPD）的维持治疗。
What This Means For Patients
Ohtuvayre (ensifentrine) is an inhaled dual PDE3/PDE4 inhibitor indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It provides both bronchodilation and anti-inflammatory benefits. Although not fully approved by NMPA in China (NDA under review as of early 2026), it can be clinically accessed in the Hainan Boao Pilot Zone.Ohtuvayre（恩司芬群）是一种吸入型双重PDE3/PDE4抑制剂，用于成人慢性阻塞性肺疾病（COPD）的维持治疗。它具有舒张支气管和抗炎的双重作用。截至2026年初，该药在中国的上市申请已获得药监局受理，目前可通过博鳌乐城先行区特许渠道引入使用。
Regulatory Approvals
- FDA — approved (2024) — label
Pivotal Clinical Evidence
- ENHANCE-1 — Anzueto et al., Am J Respir Crit Care Med 2023 (NCT04535986) — DOI
Sources
This page provides regulatory and mechanism-of-action information for reference only. It is not medical advice, a treatment recommendation, or a guarantee of outcome. Availability is subject to individual clinical review.